Batavia Biosciences

About Batavia Biosciences

Batavia Biosciences significantly contributes to ease human suffering from infectious diseases and cancer by leveraging our innovative technologies and in-depth know-how at all stages of the development trajectory, from the transition into early clinical studies, to navigating late-stage clinical development and entering commercial manufacturing at higher speed, reduced costs, and with increased success. The company operates state-of-the-art development and manufacturing facilities in Europe and the US 

  • NL
  • 2019
    On CPHI since
  • 100 - 249
Company types
Primary activities
Contract Manufacturer
Contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024

Products from Batavia Biosciences (1)

  • HIP-Vax

    Product HIP-Vax

    The demand for viral vector-based products is growing rapidly. However, there are still manufacturing challenges which hamper the development of these promising new therapies. A major problem is low product yields. For many medical applications, a certain minimal dose of product is needed to have a clinica...

Batavia Biosciences Resources (1)

  • News Batavia enters the commercial manufacturing business

    Batavia Biosciences announces that it will extend its CDMO services portfolio (R&D and clinical manufacturing) to include commercial manufacturing services. The company has finalized the design plans of its new 12.000 square meter building to be realized at the Bioscience Park in Leiden, The Netherlands. It is expected that the manufacturing facility will be operational around Q3- 2024.